Fate Therapeutics shares fall 4.17% intraday after granting non-qualified stock options to a new employee.

Fate Therapeutics, Inc. declined 4.17% in intraday trading, with the company announcing that it granted non-qualified stock options to a newly-hired non-executive employee to purchase 60,000 shares of the company’s common stock at an exercise price of $1.06 per share. This news event may have contributed to the stock's decline, as it could be perceived as dilutive to existing shareholders.